Efectividad del tratamiento farmacológico de la agresividad en pacientes con trastorno límite de la personalidad. Revisión sistemática
- View All
Introduction: Borderline Personality Disorder affects 2% to 6% of adults in the United States. It is a condition of high relevance in psychiatric disorders due to characteristics such as impulsivity, unstable interpersonal relationships, dysregulation in mood and aggressive behavior. This determines a negative impact on the functionality of the individual being aggression against self or others one of its key components. Within aggression included self-mutilation, suicidal and self-destructive behaviors such as sexual promiscuity and substance abuse. Methods: Systematic review of the literature database items and hand searching of journals related to provide the best evidence. Was evaluated methodological quality and the studies were organized in evidence tables. Results: Of 52 potential articles, five were included in this review. Were classified as evidence level Ib. Topiramate, aripiprazole, divalproex and fluoxetine showed better results than placebo especially aggression and impulsivity. Topiramate was associated with weight loss. Other effects such as headache, insomnia, constipation and nausea were less frequent. The drugs were safe and well tolerated. Discussion: The drugs tested were shown to be better than placebo. Different scales used added complexity to the interpretation of results. Conclusion: Evidence suggests that drug treatment (topiramate, aripiprazole, divalproex and fluoxetine) is effective aggressiveness and impulsivity symptoms as compared to placebo. Should be considered other studies evaluating combinations of drugs and psychotherapy.
Borderline personality disorder